Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis by Trias E et al. in Glia (2020).
Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1G93A mice by Harrison JM et al. Neurobiol Dis (2020).
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial by Mora JS et al. in Amyotroph Lateral Scler Frontotemporal Degener (2019).
Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS by Trias E et al. in JCI Insight (2018).
Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALSby Trias E et al. in JCI Insight (2018).
ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? by Petrov D et al. in Front Aging Neurosci (2017).
Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis by Trias E et al. in J Neuroinflammation (2017).
Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient by Salvado M et al. in World J Gastroenterol (2016).